Patrick R. Trucchio Analyst PerformanceBiotechnology Analyst at HC WainwrightPatrick R. Trucchio is a stock analyst at HC Wainwright in the healthcare sector, covering 29 publicly traded companies. Over the past year, Patrick R. Trucchio has issued 104 stock ratings, including buy and hold recommendations. While full access to Patrick R. Trucchio's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Patrick R. Trucchio's coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings104 Last 0 YearsBuy Recommendations99.04% 103 Buy RatingsCompanies Covered29 Unique Companies Ratings Distribution104RatingsDistribution of strong buy, buy, hold, and sell ratings by Patrick R. Trucchio.RatingPercentageCount Strong Buy0.0%0 ratings Buy99.0%103 ratings Hold1.0%1 ratings Sell0.0%0 ratingsOut of 104 total stock ratings issued by Patrick R. Trucchio at HC Wainwright, the majority (99.0%) have been Buy recommendations, followed by 1.0% Hold.Best & Worst CallsThis analyst does not have any ratings with enough history to determine best and worst calls.Exchange CoverageExchangePercentageCountNASDAQ96.6% of companies on NASDAQ28 companiesNYSE3.4% of companies on NYSE1 companyPatrick R. Trucchio, an analyst at HC Wainwright, currently covers 29 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageHealthcare29 companies100.0%Patrick R. Trucchio of HC Wainwright specializes in stock coverage within the Healthcare sector.Coverage IndustriesIndustryPercentageBIOTECHNOLOGY20 companies69.0%PHARMACEUTICALS9 companies31.0% About Patrick R. TrucchioMr. Trucchio is a Managing Director of Equity Research at H.C. Wainwright whose research focuses on biotechnology, specifically on inflammation, fibrosis, cardio-metabolic, CNS, and rare diseases in addition to other areas. Mr. Trucchio has thirteen years of research experience on the sell-side. Prior to joining H.C. Wainwright, Mr. Trucchio was a senior equity research analyst at Berenberg Capital Markets (BCM) covering biotechnology and specialty pharmaceutical companies. Prior to Berenberg Capital Markets, Mr. Trucchio worked at Wells Fargo Securities and BMO Capital Markets. At Wells Fargo, Mr Trucchio worked on an Institutional Investor ranked analyst team covering specialty pharmaceutical companies. Mr. Trucchio’s educational background includes an M.B.A. with Honors from St. John’s University and a B.S. in Finance from The Pennsylvania State University.Follow on LinkedIn Patrick R. Trucchio's Ratings History at HC Wainwright Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsARWRArrowhead Pharmaceuticals8/6/2026Boost Price Target$85.51$120.00Buy$0.0000.00% ROIDTILPrecision BioSciences8/3/2026Reiterated Rating$6.99Buy$0.0000.00% ROIALNYAlnylam Pharmaceuticals7/31/2026Lower Price Target$205.48$455.00Buy$0.0000.00% ROIARWRArrowhead Pharmaceuticals7/27/2026Boost Price Target$85.60$115.00Buy$0.0000.00% ROIGOSSGossamer Bio7/27/2026Reiterated Rating$0.19Buy$0.0000.00% ROIATAIAtai Beckley7/20/2026Downgrade$7.22$7.50Neutral$0.0000.00% ROIHRMYHarmony Biosciences7/16/2026Reiterated Rating$33.18$55.00Buy$0.0000.00% ROIALNYAlnylam Pharmaceuticals7/13/2026Boost Price Target$288.04$485.00Buy$0.0000.00% ROIDTILPrecision BioSciences7/9/2026Reiterated Rating$9.28Buy$0.0000.00% ROICMPSCompass Pathways7/8/2026Reiterated Rating$13.17$70.00Buy$0.0000.00% ROI Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. BEAMBeam Therapeutics7/7/2026Reiterated Rating$35.32$80.00Buy$0.0000.00% ROIARWRArrowhead Pharmaceuticals7/1/2026Reiterated Rating$82.09$100.00Buy$0.0000.00% ROIALNYAlnylam Pharmaceuticals6/29/2026Lower Price Target$291.37$470.00Buy$0.0000.00% ROIQUREuniQure6/29/2026Boost Price Target$47.51$80.00Buy$0.0000.00% ROIGOSSGossamer Bio6/25/2026Lower Price Target$0.17$2.00Buy$0.0000.00% ROIFTHSensei Biotherapeutics6/22/2026Initiated Coverage$17.82$60.00Buy$0.0000.00% ROIAGMBAgomAb Therapeutics6/22/2026Initiated Coverage$10.98$35.00Buy$0.0000.00% ROIIVVDInvivyd6/15/2026Reiterated Rating$0.77$10.00Buy$0.0000.00% ROIATAIAtai Beckley6/8/2026Reiterated Rating$3.95$25.00Buy$0.0000.00% ROIALNYAlnylam Pharmaceuticals6/4/2026Reiterated Rating$303.52$510.00Buy$0.0000.00% ROIDRUGBright Minds Biosciences6/1/2026Reiterated Rating$84.06$145.00Buy$0.0000.00% ROIDTILPrecision BioSciences5/27/2026Reiterated Rating$7.76$60.00Buy$0.0000.00% ROIGOSSGossamer Bio5/26/2026Reiterated Rating$0.21$5.00Buy$0.0000.00% ROIONCYOncolytics Biotech5/26/2026Reiterated Rating$0.81$10.00Buy$0.0000.00% ROIGHRSGH Research5/19/2026Lower Price Target$21.68$65.00Buy$0.0000.00% ROIANROAlto Neuroscience5/11/2026Reiterated Rating$25.45$50.00Buy$0.0000.00% ROIQUREuniQure5/6/2026Lower Price Target$21.61$50.00Buy$0.0000.00% ROIALNYAlnylam Pharmaceuticals5/5/2026Reiterated Rating$297.92$510.00Buy$0.0000.00% ROIASMBAssembly Biosciences5/4/2026Reiterated Rating$27.37$50.00Buy$0.0000.00% ROICMPSCompass Pathways4/28/2026Reiterated Rating$8.89$70.00Buy$0.0000.00% ROINRXPNRx Pharmaceuticals4/27/2026Reiterated Rating$2.94$45.00Buy$0.0000.00% ROIIMCRImmunocore4/20/2026Reiterated Rating$31.41$100.00Buy$0.0000.00% ROIIMCRImmunocore4/14/2026Reiterated Rating$31.62$100.00Buy$0.0000.00% ROIANROAlto Neuroscience4/2/2026Reiterated Rating$21.69$50.00Buy$0.0000.00% ROIASMBAssembly Biosciences3/26/2026Reiterated Rating$28.67$50.00Buy$0.0000.00% ROIALNYAlnylam Pharmaceuticals3/25/2026Reiterated Rating$325.35$510.00Buy$0.0000.00% ROIARWRArrowhead Pharmaceuticals3/25/2026Reiterated Rating$60.92$100.00Buy$0.0000.00% ROIATAIAtai Beckley3/17/2026Reiterated Rating$3.68$25.00Buy$0.0000.00% ROIVYGRVoyager Therapeutics3/17/2026Reiterated Rating$3.96$25.00Buy$0.0000.00% ROIALTAltimmune3/16/2026Boost Price Target$3.60$25.00Buy$0.0000.00% ROIThe $15 Gold Fund That Pays Up to $1,152/Month (Ad)Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required. Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away.Discover the gold income fund before the next payout dateSLNSilence Therapeutics3/13/2026Reiterated Rating$6.97$75.00Buy$0.0000.00% ROIALGSAligos Therapeutics3/11/2026Reiterated Rating$7.41$50.00Buy$0.0000.00% ROIQUREuniQure3/10/2026Reiterated Rating$17.99$70.00Buy$0.0000.00% ROIGOSSGossamer Bio3/6/2026Lower Price Target$0.52$5.00Buy$0.0000.00% ROIVIRVir Biotechnology3/4/2026Boost Price Target$8.91$20.00Buy$0.0000.00% ROIDRUGBright Minds Biosciences3/4/2026Boost Price Target$80.17$145.00Buy$0.0000.00% ROINRXPNRx Pharmaceuticals3/3/2026Boost Price Target$1.84$45.00Buy$0.0000.00% ROIPHVSPharvaris3/3/2026Reiterated Rating$27.37$60.00Buy$0.0000.00% ROIGHRSGH Research3/2/2026Boost Price Target$14.85$70.00Buy$0.0000.00% ROIATAIAtai Beckley3/2/2026Boost Price Target$3.63$25.00Buy$0.0000.00% ROICMPSCompass Pathways3/2/2026Boost Price Target$6.90$70.00Buy$0.0000.00% ROIDFTXDefinium Therapeutics3/2/2026Boost Price Target$17.45$70.00Buy$0.0000.00% ROIHELPCybin3/2/2026Boost Price Target$7.35$95.00Buy$0.0000.00% ROIHRMYHarmony Biosciences2/25/2026Reiterated Rating$28.34$55.00Buy$0.0000.00% ROIALNYAlnylam Pharmaceuticals2/18/2026Reiterated Rating$332.30$510.00Buy$0.0000.00% ROIARWRArrowhead Pharmaceuticals2/10/2026Reiterated Rating$62.56$100.00Buy$0.0000.00% ROIQUREuniQure2/10/2026Reiterated Rating$26.05$70.00Buy$0.0000.00% ROISGMOSangamo Therapeutics2/10/2026Reiterated Rating$0.40$10.00Buy$0.0000.00% ROIIMCRImmunocore2/4/2026Reiterated Rating$32.07$100.00Buy$0.0000.00% ROIALNYAlnylam Pharmaceuticals1/30/2026Lower Price Target$346.79$510.00Buy$0.0000.00% ROIGOSSGossamer Bio1/22/2026Reiterated Rating$2.74$10.00Buy$0.0000.00% ROIARWRArrowhead Pharmaceuticals1/21/2026Boost Price Target$67.01$100.00Buy$0.0000.00% ROIDRUGBright Minds Biosciences12/30/2025Reiterated Rating$79.38$115.00Buy$0.0000.00% ROIASMBAssembly Biosciences12/22/2025Reiterated Rating$36.19$50.00Buy$0.0000.00% ROINRXPNRx Pharmaceuticals12/16/2025Reiterated Rating$1.98$40.00Buy$0.0000.00% ROIMRKRMarker Therapeutics12/8/2025Initiated Coverage$1.32$10.00Buy$0.0000.00% ROIPHVSPharvaris12/3/2025Reiterated Rating$28.08$60.00Buy$0.0000.00% ROIARWRArrowhead Pharmaceuticals12/2/2025Boost Price Target$56.25$85.00Buy$0.0000.00% ROIHRMYHarmony Biosciences11/24/2025Reiterated Rating$34.78$55.00Buy$0.0000.00% ROIONCYOncolytics Biotech11/17/2025Boost Price Target$1.04$10.00Buy$0.0000.00% ROIPHVSPharvaris11/13/2025Reiterated Rating$25.81$60.00Buy$0.0000.00% ROIVYGRVoyager Therapeutics11/12/2025Lower Price Target$4.23$25.00Buy$0.0000.00% ROIGHRSGH Research11/10/2025Lower Price Target$13.54$35.00Buy$0.0000.00% ROIIVVDInvivyd10/31/2025Boost Price Target$1.81$10.00Buy$0.0000.00% ROIANROAlto Neuroscience10/24/2025Boost Price Target$11.15$50.00Buy$0.0000.00% ROIIMCRImmunocore10/22/2025Reiterated Rating$31.57$100.00Buy$0.0000.00% ROIALTAltimmune10/20/2025Reiterated Rating$3.83$12.00Buy$0.0000.00% ROINRXPNRx Pharmaceuticals10/16/2025Reiterated Rating$3.17$40.00Buy$0.0000.00% ROIPHVSPharvaris10/15/2025Initiated Coverage$20.96$60.00Buy$0.0000.00% ROIASMBAssembly Biosciences10/14/2025Reiterated Rating$27.66$50.00Buy$0.0000.00% ROIALTAltimmune10/10/2025Reiterated Rating$4.00$12.00Buy$0.0000.00% ROIBEAMBeam Therapeutics10/10/2025Reiterated Rating$27.87$80.00Buy$0.0000.00% ROIALNYAlnylam Pharmaceuticals10/10/2025Reiterated Rating$456.95$570.00Buy$0.0000.00% ROIARWRArrowhead Pharmaceuticals10/8/2025Reiterated Rating$36.54$80.00Buy$0.0000.00% ROIQUREuniQure10/6/2025Boost Price Target$54.92$110.00Buy$0.0000.00% ROINRXPNRx Pharmaceuticals10/1/2025Reiterated Rating$3.30$40.00Buy$0.0000.00% ROIHRMYHarmony Biosciences9/25/2025Lower Price Target$26.76$55.00Buy$0.0000.00% ROIQUREuniQure9/24/2025Reiterated Rating$39.80$70.00Buy$0.0000.00% ROIATAIAtai Beckley9/23/2025Reiterated Rating$5.36$15.00Buy$0.0000.00% ROISLNSilence Therapeutics9/16/2025Reiterated Rating$4.73$75.00Buy$0.0000.00% ROIThe Starlink of Energy (Ad)A portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big Tech and Washington policymakers. It can be trucked to a data center, military base, or industrial site and deliver reliable power for years without grid access. A key government milestone expected this August could bring significant visibility to this space. One small stock sits at the center of it.Read the full breakdown and see which stock to watch nowBEAMBeam Therapeutics9/15/2025Reiterated Rating$20.60$80.00Buy$0.0000.00% ROIVYGRVoyager Therapeutics9/15/2025Reiterated Rating$4.18$30.00Buy$0.0000.00% ROIDRUGBright Minds Biosciences9/15/2025Reiterated Rating$48.75$85.00Buy$0.0000.00% ROIVIRVir Biotechnology9/15/2025Reiterated Rating$4.80$15.00Buy$0.0000.00% ROIALGSAligos Therapeutics9/12/2025Reiterated Rating$10.31$50.00Buy$0.0000.00% ROINRXPNRx Pharmaceuticals9/8/2025Initiated Coverage$2.75$40.00Buy$0.0000.00% ROIQUREuniQure9/5/2025Reiterated Rating$17.56$70.00Buy$0.0000.00% ROISGMOSangamo Therapeutics9/4/2025Reiterated Rating$0.53$10.00Buy$0.0000.00% ROIALNYAlnylam Pharmaceuticals9/2/2025Reiterated Rating$446.87$570.00Buy$0.0000.00% ROIARWRArrowhead Pharmaceuticals9/2/2025Reiterated Rating$24.88$80.00Buy$0.0000.00% ROIIVVDInvivyd8/27/2025Reiterated Rating$1.03$5.00Buy$0.0000.00% ROIDRUGBright Minds Biosciences8/19/2025Reiterated Rating$42.25$85.00Buy$0.0000.00% ROIALGSAligos Therapeutics8/18/2025Initiated Coverage$7.70$50.00Buy$0.0000.00% ROIANROAlto Neuroscience8/18/2025Reiterated Rating$3.30$10.00Buy$0.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageUBS GroupCitigroupBarclaysRoyal Bank Of CanadaMorgan StanleyWells Fargo & CompanyJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupTD CowenTruist FinancialPiper SandlerDeutsche Bank AktiengesellschaftBMO Capital MarketsMizuho Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.